SOUTH SAN FRANCISCO, Calif.,
Aug. 14, 2019 /PRNewswire/
-- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported
financial results for the second quarter ended June 30, 2019 and provided an update on its
business.
Second Quarter 2019 and Recent Business Highlights
- In May 2019, Titan announced a
product purchase and supply agreement for Probuphine®
(buprenorphine) with Accredo® specialty pharmacy, a
subsidiary of Express Scripts.
- In June 2019, Titan announced a
pharmacy services agreement for Probuphine with Southside Specialty
Pharmacy.
- In June 2019, Titan and Molteni
& C. dei F.lli Alitti Società di Esercizio S.p.A. ("Molteni")
announced that the European Commission approved
Sixmo®-buprenorphine, the brand name for Probuphine
implant in the European Union ("EU").
- In July 2019, Titan announced a
specialty product distribution agreement for Probuphine with CVS
Caremark, a subsidiary of CVS Health.
- In August 2019, Titan completed
a $2.1 million offering
resulting in net proceeds of approximately $1.8 million.
"During the second quarter, we continued to build on the
foundation required to transition from a small product development
company to a successful commercial enterprise. We now have a new
user-friendly hub for processing Probuphine prescriptions and
product orders, as well as a wider and more streamlined
distribution network to support the commercialization of the
product, all of which are essential for achieving commercial
success," said Titan's President and CEO, Sunil Bhonsle. "The global footprint of
Probuphine expanded when Titan and our partner, Molteni, achieved a
major milestone in June with the approval in the EU of Sixmo. We
hope to see operational and commercial synergies as we continue
supporting Molteni in preparation for Sixmo's progressive launch
across the world's second largest market for buprenorphine-based
products, and look forward to initiating product shipments to
Molteni by the end of this year."
Probuphine is indicated for the maintenance treatment of opioid
dependence in eligible patients. Please see full indication
below.
Titan's Executive Chairman, Dr. Marc
Rubin, commented, "In addition to obtaining regulatory
approval in a third major market, we are working hard to continue
building our commercial capabilities. We are seeing an increase in
Probuphine prescribers which we believe, when combined with our
improved capabilities, will translate to product growth. Moving
forward, with sufficient resources, we can expect to see this
progress to be increasingly reflected in our financial
results."
Second Quarter 2019 Financial Results
For the three months ended June 30,
2019, Titan reported approximately $0.5 million in revenues, which reflect
approximately $0.3 million in product
revenues and $0.2 million of grant
revenues. This compared with revenues of approximately $2.7 million in the same period in 2018, which
were primarily related to license revenues from the sale of
European intellectual property rights to Molteni; and the return of
the Braeburn license and earned royalties.
Total operating expenses for the second quarter of 2019 were
approximately $5.4 million, compared
with approximately $3.3 million in
the same quarter in 2018, and consisted primarily of research and
development ("R&D") and selling, general and administrative
("SG&A") expenses and costs of goods sold, inclusive of
distribution expenses.
R&D expenses for both the quarters ended June 30, 2019 and June 30,
2018 were approximately $1.9
million. SG&A expenses for the 2019 second quarter were
approximately $3.2 million, compared
with approximately $1.4 million in
the same quarter a year ago. The increase in SG&A expenses for
the three months ended June 30, 2019
was primarily due to expenses associated with the commercialization
of Probuphine, which included increases in employee related
expenses of approximately $0.8
million, consulting and professional fees of approximately
$0.5 million, other outside services
of approximately $0.3 million, travel
related expenses of approximately $0.2
million and facilities related expenses of approximately
$0.1 million. Costs of goods sold,
which reflects product costs and other distribution expenses
associated with sales of Probuphine, were approximately
$0.2 million for the second quarter
of 2019, compared with cost of goods sold of approximately
$70,000 for the three months ended
June 30, 2018.
Net other expense was approximately $0.3
million for the three month period ended June 30, 2019, compared with net other expense of
approximately $0.2 million in the
same quarter a year ago. The increase was primarily attributable to
loss on debt extinguishment associated with the conversion of the
Molteni convertible loan.
Net loss applicable to common shareholders in the second quarter
of 2019 was approximately $5.2
million, or approximately $0.38 per share, compared with a net loss
applicable to common shareholders of approximately $0.9 million, or approximately $0.25 per share, in the same quarter in 2018.
As of June 30, 2019, Titan had
cash and cash equivalents of approximately $2.3 million. Titan believes that its cash and
cash equivalents as of June 30, 2019,
along with the approximately $1.8
million of net proceeds from the registered direct offering
and concurrent private placement completed in August 2019, will be sufficient to fund its
operation through October 2019.
Conference Call Details
Titan management will host a conference call today at
4:30 p.m. EDT to review these
financial results and discuss business developments in the period.
The conference call will be hosted by Sunil
Bhonsle, President and CEO; Dane
Hallberg, Executive Vice President and Chief Commercial
Officer; Brian Crowley, Vice
President of Finance; and Marc
Rubin, M.D., Executive Chairman.
The live conference call may be accessed by dialing
1-888-317-6003 (U.S.) or 1-412-317-6061 (international) and
providing passcode 9110840. The call will also be broadcast live
and archived on Titan's website at www.titanpharm.com/news/events.
About Probuphine
Probuphine is the only subdermal implant designed to deliver
buprenorphine continuously for six months following insertion.
Probuphine was developed using ProNeura™, the continuous drug
delivery system developed by Titan that consists of a small, solid
implant made from a mixture of ethylene-vinyl acetate and a drug
substance. The resulting construct is a solid matrix that is placed
subdermally, normally in the upper arm, in an outpatient office
procedure and removed in a similar manner at the end of the
treatment period. The U.S. Food and Drug Administration ("FDA")
approved Probuphine in May 2016, and
it is the first and only buprenorphine implant available for the
maintenance treatment of opioid addiction in eligible patients.
IMPORTANT SAFETY INFORMATION INCLUDING INDICATION AND BOXED
WARNING
INDICATION
PROBUPHINE is an implant that contains the medicine
buprenorphine. PROBUPHINE is used to treat certain adults who are
addicted to (dependent on) opioid drugs (either prescription or
illegal). PROBUPHINE is indicated for the maintenance treatment of
opioid dependence in patients who have achieved and sustained
prolonged clinical stability on low-to-moderate doses (doses no
more than 8 mg per day) of a buprenorphine-containing product.
PROBUPHINE is part of a complete treatment program that also
includes counseling and behavioral therapy.
It is not known if PROBUPHINE is safe or effective in children
less than 16 years of age.
IMPORTANT SAFETY INFORMATION
WARNING: COMPLICATIONS FROM INSERTION AND
REMOVAL OF PROBUPHINE
See Full Prescribing Information
for complete Boxed Warning
Serious complications may happen from insertion and
removal of PROBUPHINE, including:
- Nerve or blood vessel injury in your arm
- Movement of implant (migration). PROBUPHINE or pieces of it can
move into blood vessels, possibly to your lung, and could lead to
death
- Implant sticks out of the skin (protrusion)
- Implant comes out by itself (expulsion)
Call your healthcare provider right away if:
- PROBUPHINE sticks out of the skin or comes out by itself
- You have bleeding or symptoms of infection at the site after
insertion or removal, including excessive or worsening itching,
pain, irritation, redness, or swelling
- You have numbness or weakness in your arm after the insertion
or removal procedure
- You have weakness or numbness in your arm, or shortness of
breath
If the implant comes out by itself, keep it away from others,
especially children, as it may cause severe difficulty in breathing
and possibly death.
Because of the risk of complications of, migration, protrusion,
expulsion and nerve injury with insertion and removal of
PROBUPHINE, it is only available through a restricted program
called the PROBUPHINE REMS Program. Healthcare providers who
prescribe and/or insert PROBUPHINE must be certified with the
program by enrolling and completing live training.
- PROBUPHINE is not available in retail pharmacies
- PROBUPHINE must be inserted or removed only in the facility of
the certified prescriber
Implants may be difficult to locate if inserted too deeply, if
you manipulate them, or if you gain significant weight after
insertion. Your healthcare provider may do special procedures
or tests, or refer you to a surgical specialist to remove the
implants if they are difficult to locate.
The medicine in PROBUPHINE can cause serious and
life-threatening problems, especially if you take or use certain
other medicines or drugs. Call your healthcare provider right
away or get emergency help if you:
Feel faint or dizzy, have mental changes such as confusion,
slower breathing than you normally have, severe sleepiness, blurred
vision, problems with coordination, slurred speech, cannot think
well or clearly, high body temperature, slowed reflexes, feel
agitated, stiff muscles or have trouble walking.
These can be signs of an overdose or other serious
problems.
Coma or death can happen if you take anxiety medicines or
benzodiazepines, sleeping pills, tranquilizers, or sedatives,
antidepressants, or antihistamines, or drink alcohol during
treatment with PROBUPHINE. Tell your healthcare provider if you are
taking any of these medicines or if you drink alcohol.
Who should not use PROBUPHINE?
Do not use PROBUPHINE if you are allergic to buprenorphine or
any of its ingredients, this includes buprenorphine hydrochloride
and the inactive ingredient ethylene vinyl acetate or EVA.
PROBUPHINE may not be right for you. Before starting
PROBUPHINE tell your doctor about all of your medical conditions,
including:
Trouble breathing or lung problems, an enlarged prostate gland
(men), a head injury or brain problem, problems urinating, a curve
in your spine that affects your breathing, liver problems,
gallbladder or adrenal gland problems, Addison's disease, low
thyroid hormone levels (hypothyroidism), a history of alcoholism, a
history of keloid formation, connective tissue disease (such as
scleroderma), or history of MRSA infections, mental problems such
as hallucinations, an allergy to numbing medicines or medicines
used to clean your skin, are pregnant or plan to become pregnant or
are breastfeeding or plan to breastfeed.
Tell your doctor about all the medicines you take,
including prescription and over-the-counter medicines, vitamins and
herbal supplements.
What should I avoid while being treated with
PROBUPHINE?
- Do not drive, operate heavy machinery, or perform any other
dangerous activities until you know how this medication affects
you
- You should not drink alcohol during treatment. You
should not take anxiety medicines or benzodiazepines, sleeping
pills, tranquilizers, or sedatives that are not prescribed to you
during treatment with PROBUPHINE, as this can lead to slowed
breathing, drowsiness, delayed reaction time, loss of consciousness
or even death
What are the possible side effects of PROBUPHINE?
PROBUPHINE can cause serious side effects, including:
- Infection at the insertion or removal
site. Infection may happen at the implant site during
insertion or removal. Do not try to remove PROBUPHINE
yourself
- Opioid withdrawal. If PROBUPHINE comes out of your
arm or if you stop treatment, tell your doctor right away as you
can have symptoms of shaking, sweating more than normal, feeling
hot or cold more than normal, runny nose, watery eyes, goose bumps,
diarrhea, vomiting and muscle aches
- Physical dependency
- Liver problems. Call your doctor right away if you
notice signs of liver problems that may include your skin or the
white part of your eyes turning yellow (jaundice)
- Allergic reaction. If you get a rash, hives,
itching, swelling of your face, or wheezing, low blood pressure,
dizziness or decrease in consciousness
- Decrease in blood pressure. You may feel dizzy when you
get up from sitting or lying down
Tell your healthcare provider if you develop any of the
symptoms listed.
Common side effects of PROBUPHINE include: Headache,
nausea, toothache, constipation, depression, vomiting, back pain,
mouth and throat pain.
Common risks with the minor surgical procedure:
Itching, pain, irritation, redness, swelling, bleeding, or bruising
at the insertion or removal site. Scarring around the insertion
site.
Please read Full Prescribing Information,
including BOXED WARNING regarding IMPLANT MIGRATION,
PROTRUSION, EXPULSION and NERVE DAMAGE ASSOCIATED WITH INSERTION
AND REMOVAL.
Titan encourages you to report negative side effects of
prescription drugs to the FDA. You can
visit www.fda.gov/safety/medwatch/ or call
1-800-FDA-1088.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage
company developing proprietary therapeutics with its ProNeura™
long-term, continuous drug delivery technology. The company's lead
product is Probuphine® (buprenorphine) implant, a novel
and long-acting formulation of buprenorphine for the long-term
maintenance treatment of opioid dependence. Approved by the U.S.
Food and Drug Administration in May
2016, Probuphine is the first and only commercialized
treatment of opioid dependence to provide continuous,
around-the-clock blood levels of buprenorphine for six months
following a single procedure. The ProNeura technology also has the
potential to be used in developing products for treating other
chronic conditions such as Parkinson's disease and hypothyroidism,
where maintaining consistent, around-the-clock blood levels of
medication may benefit the patient and improve medical outcomes.
For more information about Titan, please visit
www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to the
commercialization of Probuphine, the regulatory approval process,
the development, testing, production and marketing of our drug
candidates, patent and intellectual property matters and strategic
agreements and relationships. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
CONTACTS:
Sunil Bhonsle,
President & CEO
(650) 244-4990
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
TITAN
PHARMACEUTICALS, INC.
|
CONDENSED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
|
(in thousands,
except per share amount)
|
(unaudited)
|
|
|
|
Three Months
Ended
June 30,
|
|
Six Months
Ended
June 30,
|
|
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
Revenue:
|
|
|
|
|
|
|
|
|
License
revenue
|
$
-
|
|
$
2,593
|
|
$
313
|
|
$
3,657
|
|
Product
revenue
|
304
|
|
75
|
|
621
|
|
75
|
|
Grant
revenue
|
198
|
|
-
|
|
513
|
|
-
|
|
|
Total
revenue
|
502
|
|
2,668
|
|
1,447
|
|
3,732
|
|
|
|
|
|
|
|
|
|
|
Operating
expense:
|
|
|
|
|
|
|
|
|
Cost of goods
sold
|
246
|
|
70
|
|
550
|
|
70
|
|
Research and
development
|
1,907
|
|
1,857
|
|
3,751
|
|
3,713
|
|
Selling, general and
administrative
|
3,231
|
|
1,380
|
|
6,313
|
|
2,995
|
|
|
Total operating
expense
|
5,384
|
|
3,307
|
|
10,614
|
|
6,778
|
Loss from
operations
|
(4,882)
|
|
(639)
|
|
(9,167)
|
|
(3,046)
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
(expense), net
|
(315)
|
|
(230)
|
|
(547)
|
|
(428)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss and
comprehensive loss
|
$ (5,197)
|
|
$
(869)
|
|
$ (9,714)
|
|
$ (3,474)
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net
loss per common share
|
$
(0.38)
|
|
$
(0.25)
|
|
$
(0.73)
|
|
$
(0.98)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
shares used in computing basic and diluted net loss per
share
|
13,576
|
|
3,534
|
|
13,397
|
|
3,534
|
CONDENSED BALANCE
SHEETS
|
(in
thousands)
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
June
30,
|
|
December
31,
|
|
|
|
2019
|
|
2018
|
|
|
|
|
|
|
Assets
|
|
|
|
|
Cash and cash
equivalents
|
$
2,292
|
|
$
9,295
|
|
Restricted
cash
|
-
|
|
361
|
|
Receivables
|
1,140
|
|
1,737
|
|
Inventory
|
1,317
|
|
1,262
|
|
Contract
assets
|
-
|
|
99
|
|
Prepaid expenses and
other current assets
|
744
|
|
547
|
|
|
Total current
assets
|
5,493
|
|
13,301
|
|
Furniture and
equipment, net
|
754
|
|
794
|
|
Operating lease
right-of-use asset
|
514
|
|
-
|
|
|
Total
assets
|
$
6,761
|
|
$
14,095
|
Liabilities and
Stockholders' Equity (Deficit)
|
|
|
|
|
Current
liabilities
|
$
4,342
|
|
$
3,452
|
|
Operating lease
liability, non-current
|
292
|
|
-
|
|
Long-term debt,
non-current
|
2,698
|
|
3,787
|
|
Derivative
liability
|
-
|
|
25
|
|
Stockholders' equity
(deficit)
|
(571)
|
|
6,831
|
|
|
Total liabilities and
stockholders' equity (deficit)
|
$
6,761
|
|
$
14,095
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-reports-second-quarter-2019-financial-results-300901904.html
SOURCE Titan Pharmaceuticals, Inc.